EXHIBIT 99.1
[LOGO OF OPHTHALMIC IMAGING SYSTEMS]
OPHTHALMIC IMAGING SYSTEMS CONTACTS:
GIL ALLON, CEO
221 Lathrop Way, Suite I Ariel Shenhar, CFO
SACRAMENTO, CA 95815 (916) 646-2020
INVESTOR RELATIONS
TODD FROMER / GARTH RUSSELL
KCSA Worldwide
212-896-1215 / 212-896-1250
FOR IMMEDIATE RELEASE
OPHTHALMIC IMAGING SYSTEMS APPOINTS INDEPENDENT DIRECTOR TO BOARD OF DIRECTORS
- - -
Professor Alon Harris Appointed to Ophthalmic Imaging Systems Scientific
Advisory Board
- - -
SACRAMENTO, CALIFORNIA, JULY 22, 2005 -- Ophthalmic Imaging Systems ("OIS") (the
"Company") (OTCBB:OISI), a leading provider of ophthalmic digital imaging
systems, today announced the appointment of Merle Symes to the Company's Board
of Directors as an independent director. Simultaneously, the Company announced
that Professor Alon Harris was appointed as the Chairman of the Steering
Committee of OIS's Scientific Advisory Board ("SAB"). Professor Harris was also
appointed as the Scientific Advisor to the Board of Directors, and is stepping
down from his current position as a member of the Company's Board of Directors.
The Board of Directors will continue to be comprised of five members following
these two changes.
Merle Symes has more than 30 years of experience in the U.S. and European
markets, managing business development, sales and marketing, and operations at
leading U.S. companies. This includes 15 years experience in the ophthalmic
industry at Bausch & Lomb and Storz Ophthalmics, formerly a division of Wyeth.
During his tenure at Bausch & Lomb, Mr. Symes served as Vice President External
Technology where he was involved with technology licensing and acquisition, and
developing technology strategies. Prior to joining Bausch & Lomb, Mr. Symes was
at Storz Ophthalmics where he served as Director of Strategic Planning and
Business Development. Currently Mr. Symes is the President and Founder of The
Provenance Group, LLC, a firm specializing in corporate strategy and innovation,
entrepreneurial ventures, M&A, and technology transfer.
Professor Alon Harris, a director of the Company since 2001, is the founder and
director of the Glaucoma Research and Diagnostic Laboratories in the Department
of Ophthalmology at the Indiana University School of Medicine. His contributions
to the SAB will further strengthen the professional and scientific foundations
which help guide the Company as it evolves into new frontiers of the eye-care
field.
221 LATHROP WAY, SUITE I . SACRAMENTO, CA 95815 . (800) 338-8436 . (916)
646-2020 . FAX (916) 646-0207 . WWW.OISI.COM
A SUBSIDIARY OF MEDIVISION IN ALLIANCE WITH AGFA
Ophthalmic Imaging Systems
Press Release
JULY 22, 2005
"We are pleased with the addition of Merle Symes to the Company's Board of
Directors. He is well versed in the ophthalmic industry with broad strategic and
business development experience. The Company continues to show strong growth,
and I look forward to working with Mr. Symes on further expanding our business"
stated Yigal Berman, Chairman of the Board of Directors of the Company. "Also,
we look forward to fully utilizing Professor Harris' broad clinical knowledge
and experience in the ophthalmology field with his appointment to the Company's
Scientific Advisory Board. He is a great asset to the Company and we look
forward to continue working together."
ABOUT OPHTHALMIC IMAGING SYSTEMS
Ophthalmic Imaging Systems, a majority-owned subsidiary of MediVision, is the
leading provider of ophthalmic digital imaging systems. The Company designs,
develops, manufactures and markets digital imaging systems and informatics
solutions for the eye care market. With over twenty years in the ophthalmic
imaging business, the Company has consistently introduced new, innovative
technology. The Company, together with MediVision, co-market and support their
products through an extensive network of dealers, distributors, and direct
representatives.
Statements in this press release which are not historical data are
forward-looking statements which involve known and unknown risks, uncertainties,
or other factors not under the Company's control, which may cause actual
results, performance, or achievements of the Company to be materially different
from the results, performance, or other expectations implied by these
forward-looking statements. These factors include, but are not limited to, those
detailed in the Company's periodic filings with the Securities and Exchange
Commission.
# # #
221 LATHROP WAY, SUITE I . SACRAMENTO, CA 95815 . (800) 338-8436 . (916)
646-2020 . FAX (916) 646-0207 . WWW.OISI.COM
A SUBSIDIARY OF MEDIVISION IN ALLIANCE WITH AGFA